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Editorial on the Research Topic
Anaphylaxis –ADistinct Immunological Syndrome, butHowMuchDoWeReally Understand?
The discovery of anaphylaxis as a clinical entity came about in 1903 during Richet and Portier’s
experiments in laboratory animals for induction of tolerance to actinotoxin (1). They reported
some interesting observations, as some animals died soon after receiving a relatively minute dose
of the toxin, after having tolerated larger doses previously. The term “anaphylaxis” originates from
the Greek word “aphylaxis” (opposite to “phylaxis” meaning “protection”). This was converted to
“anaphylaxis” as “phylaxis” was not a harmonizing or canorous linguistic expression (1).
Despite great strides in allergology and fundamental immunology during the last 2–3 decades,
and in an era of personalized and precision medicine, anaphylaxis remains a clinical diagnosis.
An important step forward has been the publication of The World Allergy Organization (WAO)
clinical criteria for anaphylaxis, which has enabled clinicians across the world to “speak the same
language” and report meaningful data (2, 3). However, these criteria have been challenged recently
campaigning for further refinement (4).
This special edition in Frontiers in Immunology (Research Topic—“Anaphylaxis”) embraces
some key areas in anaphylaxis, and provides an opportunity to appraise regarding IgE and
non-IgE mediated anaphylaxis, immunological mechanisms underlying hymenoptera venom
immunotherapy (VIT), clinical utility of serum tryptase measurements in anaphylaxis, novel
biomarkers, anaphylaxis in the elderly, refractory anaphylaxis, and peri-operative anaphylaxis
during general anesthesia (GA).
The final effector pathway in anaphylaxis is mast cell activation, which culminates into
degranulation and release of preformed vasoactive amines, prostaglandins, tryptase, and
proinflammatory cytokines that account formucocutaneous and cardio-respiratorymanifestations.
Measurement of acute serum total tryptase (AST) is the current gold standard laboratory test for
mast cell activation and Beck et al. critically analyze the clinical utility, limitations, and highlight
the value of international consensus equation in the diagnosis (5). They also summarize evidence
regarding a cautious interpretation of serum tryptase measurements in post-mortem samples and
review emerging evidence regarding novel biomarkers such as CCL-2, chymase, carboxypeptidase
A3, basogranulin, and platelet activation factor (PAF).
Allergen-specific immunotherapy is effective in IgE mediated allergy including allergic rhinitis,
bee, and wasp venom allergy and food allergy (6). It is interesting that despite development of
long-term immunological tolerance, vast majority of patients continue to demonstrate sensitization
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to the respective allergen post-treatment. Sahiner and Durham
provide an interesting overview of immunological mechanisms
underpinning VIT. The putative mechanisms underlying VIT
and other forms of allergen-specific immunotherapy has not
been fully elucidated, although research has highlighted the role
for allergen-specific Treg/Breg cells, IgG/G4 blocking antibodies,
and histamine receptor-2 in mediating peripheral tolerance
via suppression of Th2 cellular predominance and mast cell
activation. Clonal mast cell disorders such as mastocytosis are
of great relevance in hymenoptera venom allergy (7). Patients
with indolent systemic mastocytosis are usually asymptomatic
but develop severe cardiovascular anaphylaxis (with paucity of
cutaneous signs and symptoms) following a bee or wasp sting
(7, 8). The safety and efficacy of VIT in mast cell disorders has
not been well-established (9, 10) but current consensus is to
carry out VIT cautiously in those with systemic reactions after
demonstrating sensitization to the respective venom (11, 12).
Whilst majority of anaphylaxis is IgE mediated, there are
occasional scenarios where there is no evidence of sensitization.
Non-IgE mediated anaphylaxis has been proposed as a plausible
mechanism involving complement C3a/C5a anaphylatoxins
and/or IgG allergen-specific antibodies. Most evidence of non-
IgE mediated anaphylaxis comes from studies in animal models.
Kow et al. performed a meta-analysis and highlighted role for
soluble mediators including histamine, PAF, β-hexosaminidase,
IL-6, IL-13, MIP-1α, and TNF-α in IgG anaphylaxis. The main
limitation of this report is paucity of publications in this
research space.
Food allergy is a leading cause of anaphylaxis in pediatric age
group, although not uncommon in adults (2, 3). Several cases of
spontaneous anaphylaxis in adults may unfold in time as an IgE
mediated allergy to a “hidden allergen.” International migration
and travel made human diet more complex due to exposure to
diverse allergens and contributed to sensitization to new allergens
that may not be native to the patient’s geographical area. Multiple
episodes of anaphylaxis following consumption of unconnected
foods should raise the possibility for a hidden allergen-induced
or “summation anaphylaxis” due to co-factor influence. Skypala
provides an overview of hidden allergens and influence of co-
factors in food-related anaphylaxis. An accurate clinical history
with a high index of suspicion is paramount in making a correct
diagnosis (Skypala).
Another important development in our understanding of
anaphylaxis has been in relation to peri-operative anaphylaxis
during GA, refractory anaphylaxis and anaphylaxis in the elderly.
Misbah and Krishna provide an overview of peri-operative
anaphylaxis and highlight differences in etiology between the UK
and France. Recent studies from the UK have shown that latex
allergy is exceedingly rare, probably due to implementation of
latex free measures in clinical areas. Furthermore, chlorhexidine
and patent blue dye have emerged as new allergens in the peri-
operative context [Misbah and Krishna; (13)].
Occasionally, anaphylaxis may not respond despite multiple
doses of intramuscular adrenaline, i.e., “refractory.” Francuzik
et al. analyze data from the European registry in which they
report that majority of cases occurred peri-operatively due to
drug allergy and identify asthma, multiple co-morbidity, cancer,
proton pump inhibitors, aspirin, betablockers, and psychological
burden as possible contributing factors.
New therapies enhance longevity, making study of
anaphylaxis interesting in the elderly population. Aurich et
al. report data on behalf of The Network of Online Anaphylaxis
(NORA) in Europe and highlight hymenoptera venom allergy
and drug allergy as common precipitants in the elderly, and
that anaphylaxis is relatively severe in this age group with
cardiovascular involvement.
Whilst anaphylaxis is seemingly a straightforward clinical
entity for an acute care physician, its understanding for
an allergist is fairly limited at present with respect to
factors determining severity, underlying intracellular effector
mechanisms within mast cells and basophils, co-factor influence,
and immune mechanisms involving of mast cell disorders.
Future studies should approach anaphylaxis in a concerted
manner with detailed phenotyping, involvingmulti-center multi-
national studies. From a laboratory viewpoint, it is interesting
that a small proportion of cases of anaphylaxis show no
significant elevation in AST. Further studies are warranted
to explore the role for novel biomarkers in serum, urine,
and saliva.
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